Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Immunoglobulin Light-chain Amyloidosis 3Burkitt Lymphoma 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mastocytosis, Systemic 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Intraocular Lymphoma 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 17Dexamethasone 15Bortezomib 14fludarabine phosphate 12Melphalan 12Lenalidomide 10fludarabine 9Filgrastim 8pomalidomide 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Etoposide 6Whole-Body Irradiation 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Busulfan 5Antilymphocyte Serum 5sargramostim 4Sirolimus 4Panobinostat 4Mycophenolic Acid 4Methylprednisolone 4Cyclosporine 4carfilzomib 3Vorinostat 3Stem Cell Transplantation 3Prednisone 3Methotrexate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Plasma Cell × dexamethasone acetate × Clear all
NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
5 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡